← Back to Clinical Trials
Recruiting NCT03621904

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Endometrial Cancer Stage III
Sponsor Radboud University Medical Center
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex FEMALE
Min Age 18 Years
Max Age 110 Years
Start Date 2022-10-15
Completion 2026-10-15
Interventions
Hormonal Antineoplastics

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy

Eligibility Criteria

Inclusion Criteria: * Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer * All histologic types of endometrial carcinoma * Planned treatment with any type of hormonal therapy * Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy. Exclusion Criteria: * Adjuvant hormonal therapy started following complete resection of endometrial carcinoma * Synchronous use of hormonal therapy for other indications * Endometrial sarcoma or endometrial stroma cell sarcoma

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE ENDOMETRIAL CANCER STAGE III TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}